Aquatic Capital Management LLC Purchases 20,143 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Aquatic Capital Management LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 98.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,552 shares of the biopharmaceutical company's stock after purchasing an additional 20,143 shares during the quarter. Aquatic Capital Management LLC's holdings in Alnylam Pharmaceuticals were worth $9,542,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Regeneron Pharmaceuticals Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $1,045,822,000. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $577,941,000. Capital Research Global Investors lifted its stake in shares of Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after purchasing an additional 1,245,195 shares during the period. Finally, Marshall Wace LLP raised its stake in Alnylam Pharmaceuticals by 496.6% during the fourth quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock worth $89,100,000 after purchasing an additional 315,182 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ALNY. Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. StockNews.com lowered shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday. Chardan Capital reissued a "buy" rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Citigroup increased their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Finally, Stifel Nicolaus increased their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have assigned a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $315.58.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 1,561 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $398,320.37. Following the completion of the sale, the chief marketing officer now owns 13,537 shares in the company, valued at $3,454,236.29. This represents a 10.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares of the company's stock, valued at $3,654,862.41. The trade was a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,392 shares of company stock valued at $1,875,627 in the last three months. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY traded down $8.63 on Thursday, reaching $254.61. 726,549 shares of the stock traded hands, compared to its average volume of 860,439. The firm's fifty day simple moving average is $247.81 and its 200 day simple moving average is $255.70. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company has a market cap of $33.12 billion, a price-to-earnings ratio of -117.33 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12 month low of $144.73 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. The business's quarterly revenue was up 20.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.16) earnings per share. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.